Sample size in biosimilar drug product development

Journal of Bioanalysis & Biomedicine

ISSN: 1948-593X

Open Access

Sample size in biosimilar drug product development

Joint Event on 12th International Conference on Genomics and Molecular Biology & 12th European Biosimilars Congress

April 15-17, 2019 Berlin, Germany

Shein-Chung Chow

Center for Drug Evaluation and Research-US FDA, USA

Posters & Accepted Abstracts: J Bioanal Biomed

Abstract :

For the approval of biosimilar products, the United States Food and Drug Administration (FDA) recommends a stepwise approach for obtaining the totality-of-the-evidence for assessing biosimilarity between a proposed biosimilar product and its corresponding innovative (reference) biologic product. The stepwise approach starts with the assessment of analytical similarity followed by animal studies for toxicity, pharmacokinetics and pharmacodynamics (PK/PD) for pharmacological activities, immunogenicity and clinical studies for safety and efficacy. At each step, study endpoint and similarity margin for demonstration of biosimilarity are different. In this presentation, we will focus on sample size determination at each step of biosimilar product development. For illustration purpose, we will focus on the discussion of the FDA??s proposal (by adjusting similarity margin and variability associated with reference product) for selecting an appropriate sample size for analytical similarity assessment in biosimilar product development.

Google Scholar citation report
Citations: 3099

Journal of Bioanalysis & Biomedicine received 3099 citations as per Google Scholar report

Journal of Bioanalysis & Biomedicine peer review process verified at publons

Indexed In

arrow_upward arrow_upward